Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma

Authors: Sumalee Obchoei, Sarah M Weakley, Sopit Wongkham, Chaisiri Wongkham, Kanlayanee Sawanyawisuth, Qizhi Yao, Changyi Chen

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

Cyclophilin A (CypA) expression is associated with malignant phenotypes in many cancers. However, the role and mechanisms of CypA in liver fluke-associated cholangiocarcinoma (CCA) are not presently known. In this study, we investigated the expression of CypA in CCA tumor tissues and CCA cell lines as well as regulation mechanisms of CypA in tumor growth using CCA cell lines.

Methods

CypA expression was determined by real time RT-PCR, Western blot or immunohistochemistry. CypA silence or overexpression in CCA cells was achieved using gene delivery techniques. Cell proliferation was assessed using MTS assay or Ki-67 staining. The effect of silencing CypA on CCA tumor growth was determined in nude mice. The effect of CypA knockdown on ERK1/2 activation was assessed by Western blot.

Results

CypA was upregulated in 68% of CCA tumor tissues. Silencing CypA significantly suppressed cell proliferation in several CCA cell lines. Likewise, inhibition of CypA peptidyl-prolyl cis-trans isomerase (PPIase) activity using cyclosporin A (CsA) decreased cell proliferation. In contrast, overexpression of CypA resulted in 30% to 35% increases in proliferation of CCA cell lines. Interestingly, neither silence nor overexpression of CypA affected cell proliferation of a non-tumor human cholangiocyte cell line, MMNK1. Suppression of CypA expression attenuated ERK1/2 activity in CCA M139 cells by using both transient and stable knockdown methods. In the in vivo study, there was a 43% reduction in weight of tumors derived from CypA-silenced CCA cell lines compared with control vector CCA tumors in mice; these tumors with stable CypA silencing showed a reduced cell proliferation.

Conclusions

CypA is upregulated in majority of CCA patients' tissues and confers a significant growth advantage in CCA cells. Suppression of CypA expression decreases proliferation of CCA cell lines in vitro and reduces tumor growth in the nude mouse model. Inhibition of CypA activity also reduces CCA cell proliferation. The ERK1/2 pathway may be involved in the CypA-mediated CCA cell proliferation. Thus, CypA may represent an important new therapeutic target for liver fluke-associated CCA.
Appendix
Available only for authorised users
Literature
1.
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002, 37: 806-813. 10.1016/S0168-8278(02)00297-0CrossRefPubMed
2.
3.
Sonakul D, Koompirochana C, Chinda K, Stitnimakarn T: Hepatic carcinoma with opisthorchiasis. Southeast Asian J Trop Med Public Health. 1978, 9: 215-219.PubMed
4.
Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005, 41: 5-15. 10.1002/hep.20537CrossRefPubMed
5.
Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR, Thomas HC: Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol. 2006, 28: 1269-1277.PubMed
6.
Anderson CD, Pinson CW, Berlin J, Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004, 9: 43-57.CrossRefPubMed
7.
Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984, 226: 544-547. 10.1126/science.6238408CrossRefPubMed
8.
Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX: Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989, 337: 476-478. 10.1038/337476a0CrossRefPubMed
9.
Kern D, Kern G, Scherer G, Fischer G, Drakenberg T: Kinetic analysis of cyclophilin-catalyzed prolyl cis/trans isomerization by dynamic NMR spectroscopy. Biochemistry. 1995, 34: 13594-13602. 10.1021/bi00041a039CrossRefPubMed
10.
Galigniana MD, Morishima Y, Gallay PA, Pratt WB: Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex. J Biol Chem. 2004, 279: 55754-55759. 10.1074/jbc.M406259200CrossRefPubMed
11.
Syed FM, Khan MA, Nasti TH, Ahmad N, Mohammad O: Antigen entrapped in the escheriosomes leads to the generation of CD4(+) helper and CD8(+) cytotoxic T cell response. Vaccine. 2003, 21: 2383-2393. 10.1016/S0264-410X(03)00106-3CrossRefPubMed
12.
Colgan J, Asmal M, Neagu M, Yu B, Schneidkraut J, Lee Y, Sokolskaja E, Andreotti A, Luban J: Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity. 2004, 21: 189-201. 10.1016/j.immuni.2004.07.005CrossRefPubMed
13.
Andersen H, Jensen ON, Eriksen EF: A proteome study of secreted prostatic factors affecting osteoblastic activity: identification and characterisation of cyclophilin A. Eur J Cancer. 2003, 39: 989-995. 10.1016/S0959-8049(03)00068-6CrossRefPubMed
14.
Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD, Berk BC: Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000, 87: 789-796.CrossRefPubMed
15.
Sherry B, Yarlett N, Strupp A, Cerami A: Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA. 1992, 89: 3511-3515. 10.1073/pnas.89.8.3511PubMedCentralCrossRefPubMed
16.
Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC: Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006, 98: 811-817. 10.1161/01.RES.0000216405.85080.a6CrossRefPubMed
17.
Sànchez-Tilló E, Wojciechowska M, Comalada M, Farrera C, Lloberas J, Celada A: Cyclophilin A is required for M-CSF-dependent macrophage proliferation. Eur J Immunol. 2006, 36: 2515-2524. 10.1002/eji.200535270CrossRefPubMed
18.
Yang H, Chen J, Yang J, Qiao S, Zhao S, Yu L: Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun. 2007, 28: 361-763-767
19.
Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003, 63: 1652-1656.PubMed
20.
Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004, 46: 313-323. 10.1016/j.lungcan.2004.05.013CrossRefPubMed
21.
Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, Yao Q: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer. 2006, 106: 2284-2294. 10.1002/cncr.21862CrossRefPubMed
22.
Yang H, Li M, Chai H, Yan S, Lin P, Lumsden AB, Yao Q, Chen C: Effects of cyclophilin A on cell proliferation and gene expressions in human vascular smooth muscle cells and endothelial cells. J Surg Res. 2005, 123: 312-319. 10.1016/j.jss.2004.08.026CrossRefPubMed
23.
Calhoun CC, Lu YC, Song J, Chiu R: Knockdown endogenous CypA with siRNA in U2OS cells results in disruption of F-actin structure and alters tumor phenotype. Mol Cell Biochem. 2009, 320: 35-43. 10.1007/s11010-008-9896-0CrossRefPubMed
24.
Chen S, Zhang M, Ma H, Saiyin H, Shen S, Xi J, Wan B, Yu L: Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance. Cancer Chemother Pharmacol. 2008, 61: 459-469. 10.1007/s00280-007-0491-yCrossRefPubMed
25.
Li Z, Zhao X, Bai S, Wang Z, Chen L, Wei Y, Huang C: Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics. 2008, 7: 1810-1823. 10.1074/mcp.M700544-MCP200CrossRefPubMed
26.
Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005, 11: 3392-3397.PubMedCentralCrossRefPubMed
27.
Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, Okitsu T, Fukazawa T, Weber A, Stolz DB: Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 2004, 77: 446-451. 10.1097/01.TP.0000110292.73873.25CrossRefPubMed
28.
Junking M, Wongkham C, Sripa B, Sawanyawisuth K, Araki N, Wongkham S: Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer. 2008, 44: 619-626. 10.1016/j.ejca.2008.01.014CrossRefPubMed
29.
Li M, Yang H, Chai H, Fisher WE, Wang X, Brunicardi FC, Yao Q, Chen C: Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer. 2004, 101: 2341-2350. 10.1002/cncr.20634CrossRefPubMed
30.
Meloche S, Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007, 26: 3227-3239. 10.1038/sj.onc.1210414CrossRefPubMed
31.
Obchoei S, Wongkhan S, Wongkham C, Li M, Yao Q, Chen C: Cyclophilin A: potential functions and therapeutic target for human cancer. Med Sci Monit. 2009, 15: RA221-232.PubMed
32.
Wang AG, Yoon SY, Oh JH, Jeon YJ, Kim M, Kim JM, Byun SS, Yang JO, Kim JH, Kim DG: Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun. 2006, 345: 1022-1032. 10.1016/j.bbrc.2006.04.175CrossRefPubMed
33.
Harding MW, Handschumacher RE: Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications. Transplantation. 1988, 46: 29S-35S.CrossRefPubMed
34.
Wang MZ, Shetty JT, Howard BA, Campa MJ, Patz EF, Fitzgerald MC: Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. Anal Chem. 2004, 76: 4343-4348. 10.1021/ac049536jCrossRefPubMed
35.
Mikol V, Kallen J, Pflugl G, Walkinshaw MD: X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol. 1993, 234: 1119-1130. 10.1006/jmbi.1993.1664CrossRefPubMed
36.
Andersson Y, Engebraaten O, Fodstad Ø: Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer. 2009, 101: 1307-1315. 10.1038/sj.bjc.6605312PubMedCentralCrossRefPubMed
37.
Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O'Brien JM: Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2005, 46: 782-790. 10.1167/iovs.04-1022CrossRefPubMed
38.
Zupanska A, Dziembowska M, Ellert-Miklaszewska A, Gaweda-Walerych K, Kaminska B: Cyclosporine a induces growth arrest or programmed cell death of human glioma cells. Neurochem Int. 2005, 47: 430-441. 10.1016/j.neuint.2005.05.010CrossRefPubMed
39.
Ciechomska I, Legat M, Golab J, Wesolowska A, Kurzaj Z, Mackiewicz A, Kaminska B: Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. Int J Cancer. 2005, 117: 59-67. 10.1002/ijc.21153CrossRefPubMed
40.
Satoh K, Nigro P, Berk BC: Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010, 12: 675-682. 10.1089/ars.2009.2875PubMedCentralCrossRefPubMed
41.
Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, Patz EF: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 2005, 65: 8853-8860. 10.1158/0008-5472.CAN-05-1219CrossRefPubMed
42.
Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M: Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem. 2005, 280: 17013-17019. 10.1074/jbc.M412851200CrossRefPubMed
43.
Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, Guo H, Hung HC, Toole B, Gallay P: Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem. 2002, 277: 22959-22965. 10.1074/jbc.M201593200CrossRefPubMed
44.
Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, Kim SS: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 2007, 67: 3654-3662. 10.1158/0008-5472.CAN-06-1759CrossRefPubMed
45.
Yu X, Harris SL, Levine AJ: The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66: 4795-4801. 10.1158/0008-5472.CAN-05-4579CrossRefPubMed
46.
Sun S, Wang Q, Giang A, Cheng C, Soo C, Wang CY, Liau LM, Chiu R: Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-kappaB. J Neurooncol. 2011, 101: 1-14. 10.1007/s11060-010-0220-yPubMedCentralCrossRefPubMed
47.
Zhang M, Dai C, Zhu H, Chen S, Wu Y, Li Q, Zeng X, Wang W, Zuo J, Zhou M: Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem. 2011, PMID:21667159
48.
Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007, 45: 269-276. 10.1002/hep.21465CrossRefPubMed
49.
Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, Xing JL, Bian HJ, Jiang JL, Wang XH: Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006, 65: 435-444. 10.1016/j.ijrobp.2005.12.034CrossRefPubMed
Metadata
Title
Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma
Authors
Sumalee Obchoei
Sarah M Weakley
Sopit Wongkham
Chaisiri Wongkham
Kanlayanee Sawanyawisuth
Qizhi Yao
Changyi Chen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-102

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Research

Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody

Research

Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex

Research

IκB kinases increase Myc protein stability and enhance progression of breast cancer cells

Research

Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells

Research

Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis

Research

Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits